The crystal structure is shown in the figure. Tables 1 and 2 contain details on crystal structure and measurement conditions and a list of the atoms including atomic coordinates and displacement parameters.
Source of material
The title compound was synthesized starting with saccharin N-(4-(methyl)phenethyl 4-methylbenzenesulfonate). To a solution of saccharin N-(4-(methyl)phenethyl 4-methylbenzenesulfonate) (100 mg, 0.21 mmol) in acetonitrile (CH 3 CN, 10 mL) was added 1-(2-fluorophenyl)piperazine (45.36 mg, 0.25 mmol) and potassium carbonate (173 mg, 1.26 mmol). The reaction mixture was stirred at reflux for 16 h. After cooling to ambient temperature, the reaction mixture was filtered through a Buchner funnel. After filtration the filtrate was concentrated in vacuo and the residue was purified by silica gel column chromatography using ethyl acetate/petroleum ether (1/4, v/v) as eluent to afford the title compound [4] .
Experimental details
The hydrogen atoms were assigned with isotropic displacement factors U iso (H) = 1.2U eq (N and imidazol C), or U iso (H) = 1.5U eq (methyl C) and included in the final refinement by using geometrical restraints, with C-H = 0.93 Å (imidazol) or C-H = 0.96 Å (methyl), and N-H = 0.86 Å.
Discussion
The saccharin moiety has been identified as an important molecular component in various classes of 5HT1a antagonists [5] , human leukocyte elastase (HLE) inhibitors [6] [7] [8] [9] [10] , analgesics [11] , human mast cell tryptase inhibitors [12] , α1a adrenergic receptor antagonists [13] and aldehyde dehydrogenase inhibitors [14] . Moreover, compounds with arylpiperazine moieties have anti-proliferative properties [15, 16] . For these reasons, the efficient synthesis of arylpiperazine derivatives containing the saccharin moiety attract the interest of synthetic chemists. In this context, we report the synthesis of the title compound 
